The spike-and-slab lasso and scalable algorithm to accommodate multinomial outcomes in variable selection problems

AbstractSpike-and-slab prior distributions are used to impose variable selection in Bayesian regression-style problems with many possible predictors. These priors are a mixture of two zero-centered distributions with differing variances, resulting in different shrinkage levels on parameter estimates based on whether they are relevant to the outcome. The spike-and-slab lasso assigns mixtures of double exponential distributions as priors for the parameters. This framework was initially developed for linear models, later developed for generalized linear models, and shown to perform well in scenarios requiring sparse solutions. Standard formulations of generalized linear models cannot immediately accommodate categorical outcomes with > 2 categories, i.e. multinomial outcomes, and require modifications to model specification and parameter estimation. Such modifications are relatively straightforward in a Classical setting but require additional theoretical and computational considerations in Bayesian settings, which can depend on the choice of prior distributions for the parameters of interest. While previous developments of the spike-and-slab lasso focused on continuous, count, and/or binary outcomes, we generalize the spike-and-slab lasso to accommodate multinomial outcomes, developing both the theoretical basis for the model and an expectation-maximization algorithm to fit the model. To our knowledge, this is the first generalization of the spike-and-slab lasso to allow for multinomial outcomes.Keywords: Bayesian variable selectionspike-and-slabgeneralized linear modelsmultinomial outcomeselastic net Disclosure statementNo potential conflict of interest was reported by the author(s).Data availability statementCode to reproduce the results of the simulation study and data analysis is available on GitHub (https://github.com/jmleach-bst/multinomial_ssnet_analyses). Note that while code for performing analysis on ADNI data is included, the ADNI data sets themselves are not, because we are not authorized to share data from ADNI. Details for access to these data can be found at http://adni.loni.usc.edu/data-samples/access-data/.Additional informationFundingData collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health [grant number U01 AG024904] and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.;Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.;Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.